Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease

(2013) Amos A. Fatokun et al.   AMINO ACIDS

Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase

(2013) Georgios Pantouris et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Circulating Biomarkers of Tryptophan and the Kynurenine Pathway and Lung Cancer Risk

(2013) S.-C. Chuang et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients

(2013) Juan Li et al.   CLINICA CHIMICA ACTA

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)

(2013) Eduard Dolušić et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

(2013) J. Yu et al.   JOURNAL OF IMMUNOLOGY

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

(2013) Ben C. Creelan et al.   OncoImmunology

Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation

(2012) NAOTO SATO et al.   ONCOLOGY REPORTS

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells

(2011) Jingyan Sun et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Kynurenine metabolism in health and disease

(2010) Lukasz R. Kolodziej et al.   AMINO ACIDS

IDO inhibits T-cell function through suppressing Vav1 expression and activation

(2010) Runmei Li et al.   CANCER BIOLOGY & THERAPY

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

(2010) Alexander J. Muller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy

(2010) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers

(2010) Barbara Sperner-Unterweger et al.   IMMUNOBIOLOGY

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells

(2009) D. J. Chung et al.   BLOOD

Interferon- -triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells

(2009) B. Jurgens et al.   BLOOD

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

(2009) Takeshi Yoshikawa et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC–tandem mass spectrometry

(2009) Wilhelmina H.A. de Jong et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine

(2009) H.-J. Ko et al.   JOURNAL OF IMMUNOLOGY

IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells

(2009) B. Baban et al.   JOURNAL OF IMMUNOLOGY

Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer

(2009) Yuzo Suzuki et al.   LUNG CANCER

Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

(2008) E. S. Jordanova et al.   CLINICAL CANCER RESEARCH

Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival

(2008) K. Ino et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ

(2008) Selim Corm et al.   LEUKEMIA RESEARCH

Evolving immunosuppressive microenvironment during human cervical carcinogenesis

(2008) A Kobayashi et al.   Mucosal Immunology

Immune escape as a fundamental trait of cancer: focus on IDO

(2008) G C Prendergast   ONCOGENE

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

(2008) A. J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA